ZIEXTENZO

Manufacturer:

Sandoz

Name:

ZIEXTENZO

HCPCS Code Descriptor:

Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg

Category:

Q Code

HCPCS:

Q5120

NDC(s):

61314-0866-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic Status:

Single-Source

Route of Administration:

Subcutaneous

About:

ZIEXTENZO is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Sandoz and administered via the Subcutaneous route of administration. The Q Code: Q5120 is aligned to the drug ZIEXTENZO.

Ziextenzo (pegfilgrastim) is used to prevent the lack of certain white blood cells (neutrophils) in the body by aiding in the production of these white blood cells. This medication is manufactured by Sandoz and is biosimilar to the drug Neulasta (J2506). Ziextenzo was aligned to the HCPCS code Q5120 July 2020. Patient assistance programs for this medication can be found through the Sandoz One Source program.